Gentian Diagnostics AS (OSL:GENT) Total Current Liabilities: kr32.6 Mil (As of Mar. 2026)


OSL:GENT Gentian Diagnostics AS OSL:GENT
73 GF Score
Price kr37.00
GF Value kr61.88
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Gentian Diagnostics AS Total Current Liabilities?

Gentian Diagnostics AS OSL:GENT -4.88% 73 Total Current Liabilities is kr32.6 Mil as of Mar. 2026. GuruFocus rates OSL:GENT with a GF Score™ of 73/100 and a GF Value™ of kr61.88 (Possible Value Trap). The stock has 1 warning sign investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Gentian Diagnostics AS's total current liabilities for the quarter that ended in Mar. 2026 was kr32.6

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Gentian Diagnostics AS Total Current Liabilities Related Terms

Gentian Diagnostics AS Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Gentian Diagnostics AS's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gentian Diagnostics AS Total Current Liabilities Chart

Gentian Diagnostics AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.55 22.00 25.32 30.11 34.14

Gentian Diagnostics AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.09 30.59 28.75 34.14 32.58
OSL:GENT
73GF Score
Gentian Diagnostics AS OSL:GENT
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gentian Diagnostics AS Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Gentian Diagnostics AS's Total Current Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=8.874+3.547
+Other Current Liabilities+Current Deferred Liabilities
=21.719+0
=34.1

Gentian Diagnostics AS's Total Current Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=32.583+0
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=32.6

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of kr32.6 Mil mean?
Gentian Diagnostics AS (OSL:GENT) has a Total Current Liabilities of kr32.6 Mil as of Mar. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Gentian Diagnostics AS and its competitors.
Is Gentian Diagnostics AS's Total Current Liabilities too high?
Gentian Diagnostics AS's current Total Current Liabilities is kr32.6 Mil. Overall, Gentian Diagnostics AS has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gentian Diagnostics AS's Total Current Liabilities compare to ABT and SYK?
Gentian Diagnostics AS's Total Current Liabilities of kr32.6 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Medical Devices & Instruments company?
A good Total Current Liabilities depends on the Medical Devices & Instruments industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Gentian Diagnostics AS and its competitors. Gentian Diagnostics AS's current Total Current Liabilities is kr32.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gentian Diagnostics AS stock overvalued right now?
Based on GuruFocus' analysis, Gentian Diagnostics AS (OSL:GENT) is currently considered Possible Value Trap. The stock's GF Value™ is kr61.88, compared to a current price of kr37.00 — trading 40.2% below its estimated fair value. The current Total Current Liabilities is kr32.6 Mil. Gentian Diagnostics AS's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Gentian Diagnostics AS (OSL:GENT), the current Total Current Liabilities is kr32.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gentian Diagnostics AS (OSL:GENT) Overvalued in 2026?

Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued. The current stock price of kr37.00 is trading 40.2% below its estimated GF Value™ of kr61.88. GuruFocus considers Gentian Diagnostics AS to be Possible Value Trap.

Key valuation signals for OSL:GENT:

  • Total Current Liabilities: kr32.6 Mil
  • GF Value™: kr61.88 vs. price of kr37.00 (40.2% below fair value)
  • GF Score™: 73/100 with 1 warning sign

No single metric tells the full story. See the OSL:GENT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gentian Diagnostics AS Business Description

Other Exchanges GENTOo:Sweden6FK:Germany
Address Bjornasveien 5, Moss, NOR, 1596
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
73GF Score

Get the complete analysis for OSL:GENT

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr37.00
Price
kr61.88
GF Value